Sorafenib/Nexavar medical insurance reimbursement conditions and requirements

Sorafenib/Nexavar (Sorafenib), as one of the targeted anti-liver cancer drugs recognized at home and abroad, has been on the market in China for many years and has been included in the national medical insurance directory. The current medical insurance application scope of sorafenib is mainly concentrated on liver cancer. In other words, only patients who are clearly diagnosed with advanced primary liver cancer and cannot undergo surgery, local ablation or transarterial chemoembolization (TACE) treatment can meet the basic requirements for medical insurance reimbursement. Such people are often already in the intermediate and advanced stages, and traditional treatments are not effective. Therefore, targeted intervention with sorafenib has become an important option to delay disease progression.

After sorafenib entered the medical insurance, the price dropped significantly compared with the past, which greatly eased the financial burden of patients. At present, in most provinces and cities, the personal out-of-pocket ratio after medical insurance reimbursement has been controlled at around 30%, but the specific reimbursement ratio still needs to be determined based on factors such as regional medical insurance policies, hospital levels, insurance types (such as employee medical insurance or resident medical insurance), and whether regular prescriptions are issued. Some regions also require patients to provide tumor pathology reports, imaging diagnoses, and multidisciplinary consultation records as the basis for reimbursement to ensure the rational use of drugs and the reasonable allocation of medical insurance funds.

In addition, sorafenib is a Class B drug. Before reimbursement in some areas, doctors must fill in a specific application form based on the patient's condition, and it can only be included in reimbursement after review by the medical insurance agency. Some provinces and cities have adopted a "dual-channel" policy that allows you to enjoy medical insurance settlement after purchasing medicines at designated retail pharmacies, further improving the accessibility of medicines. For indications other than liver cancer, such as kidney cancer or thyroid cancer, they are currently not covered by medical insurance in most areas, and patients need to pay the full amount out of their own pocket, unless special local policies are introduced.

Reference materials:https://www.nexavar.com/